Fragmin® 5000 IU, Abelacimab 150 mg/ml solution for infusion clinical trials

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

This study looks at a new medicine called abelacimab for people with cancer-related blood clots. It compares abelacimab to a common blood thinner, dalteparin, to see which is better at preventing new clots and causing fewer bleeds.